A new study by Indiana University School of Medicine researchers has revealed a breakthrough in the fight against acute myeloid leukemia, one of the most aggressive and fatal blood cancers in adults.

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

Of 34 CMML treatment-naïve participants enrolled and treated with lenzilumab plus azacitidine, 22 have evaluable responses in the first twelve months of follow-up - Building upon previously reported ...

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with certain subtypes of acute myeloid leukemia (AML).

MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.Sophie Paczesny, ...

Scientists at Indiana University School of Medicine have identified a new approach that could transform treatment for acute ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

A watercolor set gifted during my bone marrow transplant for acute myeloid leukemia became my outlet for wonder, creativity, ...

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...

Panelists highlight that patient advocacy is crucial in improving high-risk acute myeloid leukemia (AML) outcomes by ...

Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal.